You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

February 26, 2013

Online Pharmacies in Thailand: Potential Risks

Informed Counsel

“Save 30% if you buy today!” This is just one of many familiar e-commerce advertisements that regularly bombard consumers online. By employing many of the same techniques that have proven to be successful in selling other goods, many online pharmacies advertise drugs in an aggressive fashion to increase their sales.

Of course, online pharmacies offer certain advantages. They help consumers find the specific drug products they need, and they often offer special discounts. Online pharmacies are also easy to access—a simple web search reveals a seemingly endless list of online pharmacies. Furthermore, if a customer feels embarrassed about purchasing certain types of products, such as erectile dysfunction medication, from an actual pharmacy, a virtual pharmacy can help prevent an uncomfortable experience.

But despite these conveniences, there are some important risks associated with online pharmacies and the products they sell. Large quantities of drugs can be dispensed, which may raise the possibility of drug abuse. A further important risk is posed by counterfeit medication; drug products purchased online may be counterfeit, illegal, or unapproved by Thailand’s Food and Drug Administration (FDA).

Web Pharmacy Hosted in Thailand: Illegal Products and Consequences

The Pittsburgh Post-Gazette published a story about a 33-year-old Thai woman who was the head of a company running a website, www.eDrugnet.com, plus at least 30 other affiliated websites. These sites sold drugs without prescriptions, despite the fact that they were required. These e-pharmacy websites were hosted in Thailand and shipped drugs to the United States. The company received e-mails with drug orders from customers and would send drugs overseas in boxes labeled as samples and gifts via express mail.

After a lengthy investigation by the U.S. FDA, FBI, and Department of Homeland Security, which involved meeting the woman in Bangkok and ultimately causing her to fly to the United States to meet undercover agents, the woman confessed to the scheme. She pleaded guilty in federal court to wire fraud, money laundering, and introducing misbranded drugs to the United States. The Thai businesswoman is suspected of having made over USD 2.1 million. Her website has been taken offline, and her income and the assets from the business could be seized following the court sentencing, which is set for February 22, 2013.

Legislation in Thailand Governing Online Pharmacies

There is no separate legislation governing the online sale of pharmaceutical products through web pharmacies hosted in Thailand. The Drug Act B.E. 2510 (1967), which is applicable to the physical sale of medicinal and pharmaceutical products, also regulates the online sale of such products.

According to Section 14 of the Drug Act, the licensing authority (the Thai FDA) will approve a “license to sell drugs” for business operators if they comply with certain requirements. One of the requirements is that the business operator, a resident in Thailand, has the premises to sell or store drugs, equipment for use in the sale or storage of drugs, and control over the maintenance of drug quality and quantity, as prescribed in the ministerial regulations. In addition, Section 21 of the Drug Act states that a business operator that has been permitted to sell modern drugs must have a pharmacist on duty during business hours. These two sections of the Drug Act restrict the distribution of drugs “virtually,” since both the requirements of appropriate premises and a pharmacist on duty are unmet.

Using the Internet and Social Media for Drug Advertising

Despite the fact that it is not legal under Thai law to market drug products online, more and more pharmacies are now turning to social media marketing as a promotional channel. Many pharmacies are creating fan pages via social media as part of a “direct-to-consumer advertising” strategy.

However, business operators need to understand that information distributed on the internet, intended for customers in Thailand, must meet the same requirements as other media distribution. While there are no specific rules on the use of the internet or social media for drug advertisements, the Thai FDA enforces and regulates the promotion of drugs via Sections 88 to 90 of the Drug Act. Under Section 88 bis, advertisements to sell drugs via radio, television, movies, or through printed matter must receive permission from the Thai FDA for the text, sound, or picture used in the advertisement.

Nevertheless, most advertisements (more than 85 percent) on the internet are being presented without permission, according to the Thai FDA. Currently, the FDA has made it a priority to deal with this problem. Thus, business operators must ensure that their social media marketing strategy meets FDA requirements, as well as the requirements of the Drug Act. Any violation of the Drug Act’s marketing provision is subject to a fine of up to THB 100,000 (USD 3,330).

Increasing Enforcement

Thailand’s current drug laws are more than forty years old, and therefore are not well suited to deal with e-commerce. Although it is not legally permissible to market drug products online in Thailand, the illegal online pharmacies that do still exist pose threats to consumers in regard to the method of distribution, which may increase the likelihood of drug abuse, and further run the risk of medication being counterfeit. Thai pharmaceutical businesses should assess whether their e-commerce and marketing activities violate drug laws, especially as national and international authorities are stepping up their efforts to prevent the further proliferation of illegal online pharmacies.

RELATED INSIGHTS​ 

January 5, 2026
On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam. According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity. Some of the key stipulations of Circular 57 are outlined below. Basis for Determining Technical Standards and Quality Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means: Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations; Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and Documentation evidencing compliance provided by the medical device owner. The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions. Classification of Medical Devices Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality. Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam. Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam. Outlook Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027. Holders of medical
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted
November 25, 2025
Food safety incidents can emerge without warning, requiring businesses to act swiftly to protect consumers and comply with regulatory obligations. Across Southeast Asia, Thailand, Vietnam, and Indonesia have each developed comprehensive food recall frameworks designed to ensure rapid removal of unsafe products from the market while holding businesses accountable for compliance failures. While these three jurisdictions share common objectives—protecting public health and ensuring food safety—each has crafted distinct regulatory approaches reflecting their unique administrative structures, enforcement priorities, and legal traditions. Understanding these differences is essential for food businesses operating in the region, as recall procedures, timelines, reporting requirements, and penalties vary significantly across borders. This guide, available through the button below, examines the food recall regulations in Indonesia, Thailand, and Vietnam, providing practical guidance on legal requirements, procedural steps, and compliance obligations in each market.